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The human immunodeficiency virus (HIV) has infected millions of people since
the start of the epidemic in the early 1980s. HIV is the etiologic agent of the
acquired immunodeficiency syndrome (AIDS), which has taken millions of lives.
It is extremely difficult for particular populations to receive medication to treat
HIV infection and prevent the progression of HIV to AIDS. Multiple studies have
examined the effect of vitamin A on HIV infection, due to its immune stimulating
effects. It is unclear whether an association exists between vitamin A and
different aspects of HIV. This review examined the effect of vitamin A status
and/or supplementation on components of HIV/AIDS. Multiple studies
determined if vitamin A was associated with a decreased risk in mortality among
HIV-infected individuals. Although results were controversial, a majority found
vitamin A status or supplementation significantly reduced the risk of mortality in
HIV-positive individuals. However, researchers did not find strong results
regarding vitamin A and morbidity. Although status was linked to a decrease in
diarrheal morbidity, a major cause of hospital admission and even death in many
developing countries, it appeared that vitamin A did not have a significant effect
on other aspects of morbidity. It was unclear whether vitamin A had an effect on
CD4+ T cell count, as studies had controversial results. The same was determined
for vitamin A’s effect on HIV progression to AIDS. Although these results have
positive implications for using vitamin A as an adjunct to standard HIV treatment,
no recommendations have been made regarding vitamin A supplementation and
HIV status. Additional research is necessary to determine if vitamin A could be
used as a potential therapy for HIV-infected individuals.

The association between Vitamin A status or supplementation and HIV/AIDS
Introduction
According to the World Health Organization (WHO), nearly 78 million people have been
infected with the human immunodeficiency virus (HIV), and roughly 39 million people have
died of the acquired immunodeficiency syndrome (AIDS) since the start of the epidemic in 1981
(WHO, NDb; U.S. Department of Health and Human Services [USDHHS], 2015a). Globally, an
estimated 35 million people were living with HIV at the end of 2013 (WHO, NDb). Only 0.8%
of the global population of adults 15-49 years old are infected with HIV; however, the
prevalence rates vary greatly by region and country, with Sub-Saharan Africa being most
severely affected, with nearly one in every 20 adults living with HIV, accounting for nearly 71%
of people living with HIV worldwide (WHO, NDb). This disparity results from lack of
education, medicine and treatments, and testing/prevention services. Figure 1 below illustrates
the prevalence of HIV by WHO region.

Figure 1. Prevalence of HIV infection by WHO region. From WHO
(NDb).
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It is apparent that Africa most greatly suffers from HIV infection, with a prevalence of
4.5, although the Americas are in danger of the epidemic as well, with a prevalence of .5—a
higher prevalence than the all the remaining WHO regions (WHO, NDb).
In the United States, more than 1.2 million people aged 13 years and older are living with
HIV, and roughly one in eight are unaware of their infection (Centers for Disease Control and
Prevention [CDC], 2015). The number of new HIV infections has remained fairly stable over the
past few years in the United States, with an estimated incidence of 50,000 new cases each year,
indicating a need for intervention and prevention (CDC, 2015). With treatment and a healthy diet
and lifestyle, HIV is manageable; individuals can live years, even an entire lifetime before
progressing to AIDS. However, without treatment, about 50% of HIV positive individuals
progress to AIDS within 10 years and roughly 75% of individuals with HIV will develop AIDS
within 15 years (Rodriguez, 2010). With these staggering statistics, it is crucial to find a way to
prevent or slow progression to AIDS.
HIV/AIDS
Acute HIV Infection Stage
The human immunodeficiency virus is the etiological agent of AIDS (Martinez, 2015).
Within two to four weeks after infection, individuals may experience flu-like symptoms,
including fever, chills, rash, night sweats, muscle aches, sore throat, fatigue, swollen lymph
nodes, and mouth ulcers, although some people do not experience any symptoms at all
(USDHHS, 2015d). These symptoms may last from a few days, up to multiple weeks; however,
some do not experience any symptoms of infection for up to 10 years (USDHHS, 2015d). During
this stage, there is a high risk of transmitting the infection to others, so it is critical to take
precautionary measures (USDHHS, 2015d).
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Clinical Latency Stage
After immediate HIV infection, the disease progresses into a clinical latency stage, also
called “chronic HIV infection” (USDHHS, 2015c). During this stage, HIV is still active in the
body, but reproduces at low levels (USDHHS, 2015c). At this point, people can manage their
infection by controlling environmental factors. Many individuals start antiretroviral therapy
(ART), often called highly active antiretroviral therapy (HAART), which is a combination of
multiple antiretroviral medications used to slow the rate at which HIV multiplies (WebMD,
2014). Additionally, individuals can manage their stress levels, exercise, get vaccinated, eat a
well balanced diet, and live a healthier lifestyle to help control the spread of infection, and
decrease their risk of getting other opportunistic infectious diseases (Rodriguez, 2010). The
length of this stage of infection varies by individual, but can last a decade or longer, while others
may progress very quickly.
Progression to AIDS
AIDS is clinically defined as having fewer than 200 CD4+ T cells/ml of blood (Martinez,
2015). CD4+ T cell counts in a healthy individual range from 500 to 1200 cells/ml (USDHHS,
2015b). Progression to AIDS also occurs when one or more opportunistic infections such as
EBV lymphoma, Kaposi’s sarcoma, aseptic meningitis, candida, Mycobacterium, or Treponema
is acquired, regardless of CD4+ T cell count (Martinez, 2015; USDHHS, 2015c). Once an
individual has progressed to this stage, he or she may experience rapid weight loss; recurring
fever; extreme fatigue; diarrhea that lasts for more than a week; sores of the mouth, anus, or
genitals; memory loss, depression, or other neurological disorders; as well as other symptoms
from the associated infectious disease (USDHHS, 2015d). Often, these symptoms are related to
the opportunistic infectious disease, due to the body’s decreased immune system (USDHHS,
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2015d). Without treatment, people who are diagnosed with AIDS typically survive three years,
and once an individual develops a dangerous opportunistic infection, life expectancy drops to
about one year (USDHHS, 2015c). Some factors that affect the time it takes to progress to AIDS,
like age and subtype of HIV, cannot be altered. However, others, such as getting appropriate
nutrition, adequate exercise, keeping a low level of stress, taking medications properly, and
maintaining as healthy an immune system as possible can be controlled in order to delay or
prevent the progression from HIV to AIDS (USDHHS, 2015c).
The Immune System
Background. The immune system is a complex body of molecules, cells, and organs that
work together to keep the human body healthy, free of disease, and functioning at the highest
efficiency possible. There are many components to the immune system, including innate
immunity and adaptive immunity (Winstead, 2015). Innate immunity involves defenses that are
present at birth, such as skin, mucous membranes, phagocytes, and fever (Shields, 2015).
Adaptive immunity develops after an individual is exposed to an infectious agent, and involves B
lymphocytes and T lymphocytes (B cells and T cells, respectively) (Shields, 2015). An
individual’s skin and mucous membranes are the first lines of defense to an infection, due to
their barrier-like and antimicrobial properties (Shields, 2015; Winstead, 2015). The skin provides
a shield, or barrier, between the outside world and the inside of the body. If this barrier is broken,
there is a significant increased risk of infection. Additionally, both the skin and mucous
membranes contain protective chemicals that inhibit or destroy microorganisms, such as the low
pH of three to five of skin, lipids in sebum, dermcidin in sweat, or lysozyme of saliva and
lacrimal fluid (Shields, 2015).
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If the body’s innate immune system is overwhelmed and cannot rid itself of an infection,
the adaptive immune system will be mobilized (Shields, 2015; Winstead, 2015). B cells mediate
humoral immunity, while T cells make up cell-mediated immunity (Shields, 2015). B cells must
be activated by T helper cells, and then can produce antibodies, which recognize specific
antigens (a substance that is recognized by the immune system and provokes an immune
response) on foreign bodies and attack them using different mechanisms in order to destroy the
organism (Shields, 2015; Winstead, 2015). Cellular immunity is mediated by T cells, which are
divided into cytotoxic T cells (CD8+ T cells), which induce cells that are infected with viruses to
undergo apoptosis, and helper T cells (CD4+ T cells), which activate other cells of the immune
system (Shields, 2015; Winstead, 2015). Helper T cells are responsible for activating other T and
B cells, inducing T and B cell proliferation, and activating macrophage and other immune cells
(Shields, 2015; Winstead, 2015). Without the CD4+ T cell, there is no immune response
(Shields, 2015).
The immune system and HIV. When an individual is exposed to the human
immunodeficiency virus, the skin and mucous membranes are the first barriers (Martinez, 2015).
If the virus crosses these barriers, it interacts with host cells, infects CD4+ T cells, is delivered to
lymph nodes and is actively replicated in lymphoid tissue, and eventually disseminates causing
systemic viremia (Martinez, 2015). The human immunodeficiency virus destroys CD4+ cells by
using the cells’ machinery to replicate, thereby depressing cell-mediated immunity, allowing for
HIV replication in cells to occur and increasing risk for contracting other opportunistic infections
(Martinez, 2015; Shields, 2015; USDHHS, 2015b). Murphy et al. (2001) found in their clinical
trial that CD4+ lymphocyte counts, along with HIV RNA level, was a strong determinant of HIV
mortality and opportunistic events, which was consistent with other literature (Murphy et al.,
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2001). This demonstrates that CD4+ T cell counts and the immune system play important roles
in HIV progression.
Nutrients and the immune system. An all-encompassing balanced and healthy diet is key
to having a strong immune system. This is especially important for those who are HIV positive,
as this influences risks for contracting infectious diseases that can lead to progression to AIDS
and death. Some nutrients of particular importance are vitamin A and beta-carotene, the B
vitamins, vitamin C, vitamin E, iron, selenium and zinc (The U.S. Department of Veteran’s
Affairs [USDVA], 2015b). All of these nutrients help keep the immune system healthy and
strong, with some having specific roles. For instance, vitamin E helps protect cells and helps
resist infections, while vitamin C helps protect the body from infection and aids in recovery
(Food and Agriculture Organization of the United Nations [FAO], ND; USDVA, 2015b).
Additionally, vitamin A keeps the skin, lungs, stomach, and epithelial and mucosal barriers
healthy (Reaves, 2015; USDVA, 2015b). While it is best to obtain nutrients through ingestion of
food, sometimes supplementing with single or multivitamins is necessary, and can be extremely
beneficial, especially those who are at risk of deficiency.
Current Treatments
Highly active antiretroviral therapy. Currently, the standard treatment for HIV infection
is highly active antiretroviral therapy, or HAART (WebMD, 2014). HAART is sometimes
referred to as ART, but they are in fact the same treatment and can be used interchangeably.
HAART is the combination of three or more antiretroviral medicines, often referred to as an
“anti-HIV cocktail,” used to slow the rate of HIV replication in the body (WebMD, 2014).
According to Delaney (2006), in roughly ten years, the death rate from AIDS was reduced by
50% to 80% and changed from a nearly universally fatal disease to a manageable chronic illness
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(Delaney, 2006). The author attributes this drastic change in mortality rates to the development
and use of ART. A study in 2001 examined the effect of HAART on individuals with advanced
HIV (Murphy et al., 2001). The researchers were particularly interested in the effect on
cytomegalovirus retinitis (CMV retinitis), inflammation of the retina that can lead to blindness
and predominantly occurs in individuals with compromised immune systems, but also observed
were mortality rates, non-CMV opportunistic events, and the number of red blood cell
transfusions related to anemia that individuals needed (Murphy et al., 2001). The results showed
significantly decreased mortality rates and rates of non-CMV related opportunistic events in HIV
advanced individuals after HAART (Murphy et al., 2001). Table 1 below illustrates these
findings.
Table 1. Event rates and rate ratios for death, opportunistic events, and red
blood cell transfusion, by HAART status*

From Murphy et al. (2001).
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Although HAART has saved thousands, if not millions of lives, it has a strict regimen
that individuals often find adherence to difficult. Antiretroviral therapy medications must be
taken exactly as they are prescribed, and need to be continued indefinitely in order to maintain
suppressed viral loads and prevent emergence of drug resistant mutations (AIDSInfo, 2016).
Studies have found that HAART is characterized by negative side effects including nausea,
vomiting, diarrhea, fatigue, sleep disturbances, fat redistribution, and skin problems, which lead
to decreased drug regimen adherence (Johnson & Folkman, 2004). Additionally, with wholesale
prices of ART ranging from $300 to over $3,700 per month, many individuals are not able to
afford this treatment, while others may not take their medication exactly as prescribed in order to
prolong the refilling of their prescriptions (AIDSInfo, 2015). While some individuals may not be
able to afford these medications, there are entire countries that cannot afford, or even imagine a
treatment like HAART. While agencies like the Gates Foundation have greatly increased the
number of individuals receiving ART, particularly in Sub Saharan Africa, only about half of all
people needing treatment receive it (Bill and Melinda Gates Foundation, ND). Figure 2 on the
following page presents the number of people receiving ART by WHO region and the increase in
ART coverage over the last 15 years.
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Figure 2. Estimated numbers of people receiving antiretroviral therapy
globally and by WHO Region and percentage coverage globally, 2000-2015.
From WHO (NDa).
Although the number and percentage of people receiving ART has greatly increased in
the last 15 years, a majority of the world’s population is still not covered. It may appear that the
African Region is receiving much of the antiretroviral therapy; however, Africa also has the
largest percentage of individuals infected with HIV, 71% of worldwide infections to be exact
(WHO, NDb). Therefore, though Africa may be receiving most of the treatments, the percentage
of people receiving ART does not compare to the number of infections. Figure 3 on the
following page illustrates this lack of ART coverage worldwide.
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Figure 3. Number of people receiving ART and percentage of all people
living with HIV receiving ART in low- and middle-income countries overall
and by WHO region, 2013. From Martinez (2015).
There is a clear disparity between the percentage of people receiving ART and those who
need it, not only in Africa, but globally. For instance, in the United States, an estimated 1.2
million people were living with HIV in 2013, while only 37% had ART coverage, and only 30%
of that population had a suppressed viral load (Avert, 2015b). However, in the United Kingdom,
although a much smaller percentage of the population is infected with HIV, roughly 104,000 in
2014, 91% of adults had ART coverage, and 95% of them had suppressed viral load (Avert,
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2015a). The difference in percentages that receive ART by country is staggering. Although the
percentage of ART coverage has increased, the number of newly infected individuals each year
outnumbers those who gain access to treatment by two to one (Bill and Melinda Gates
Foundation, ND). Serious public health research needs to be conducted, and measures need to be
put into action in order to increase the availability of ART to nations in need.
Exercise. Exercise is important in maintaining health, regardless of HIV status. Although
exercise does not treat HIV, it can help increase many aspects of quality of life. Exercising can
reduce stress, help with depression, and increase an overall sense of wellbeing (USDVA, 2015a).
In 2008, a study was conducted to examine the effects of exercise on quality of life in HAARTtreated, HIV-positive individuals with body fat redistribution in Rwanda (Mutimura, Stewart,
Crowther, Yarasheski, & Cade, 2008). Body fat redistribution (BFR) is a common side effect of
HAART, which may reveal a person’s serostatus, resulting in stigmatization and decreased
psychosocial wellbeing (Mutimura et al., 2008). This study not only found anthropometric and
body composition changes, but also quality of life improvements in the exercise group versus the
control group (Mutimura et al., 2008). Such improvements involved psychological,
independence, social relations, and HIV HAART- specific domains of life. Subjects in the
exercise group reported significantly fewer problems feeling ashamed in public, fewer problems
related to dressing style and size, more confidence in their health, had less fear of forced HIV
status disclosure, and were less embarrassed due to the impact of body changes (Mutimura et al.,
2008). Although this was one of the only trials to date that evaluated the effect of exercise on
quality of life in HIV-positive individuals, there was a strong correlation between the two.
Additionally, exercise can help increase muscle mass as well as improve appetite, which are
important components, as many HIV positive individuals experience wasting with harmful
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effects. Being physically active can also improve an individual’s sleep as well his or her immune
system (USDVA, 2015a).
Nutrition. Having an encompassing diet filled with fresh fruits and vegetables, whole
grains, and an adequate amount of protein, fat, and complex carbohydrate is especially important
for those who are diagnosed HIV-positive. Unfortunately, those who are infected with HIV are
often unable to meet the Recommended Dietary Allowance (RDA) for certain macro and
micronutrients due to food insecurity, low socioeconomic status, malabsorption, and decreased
appetite, even though they have increased needs (FAO, ND). This can have a detrimental effect
on an individual’s HIV status. It is best to meet the RDA for vitamins and minerals through food
sources, but if resources are not available or intake is decreased for other reasons, supplements
can be an effective alternative to meet the RDA. Many vitamins and minerals play critical roles
in maintaining a healthy immune system and keeping the body functioning properly and
efficiently, such as the B vitamins, vitamin C, iron, selenium, zinc, and vitamin A (FAO, ND;
USDVA, 2015b). A low intake of these and other vitamins and minerals can have many health
implications for those who are HIV/AIDS-positive.
Vitamin A
Definition and RDA
Vitamin A is a broad term to characterize a family of fat-soluble dietary compounds that
are found in yellow, orange, and red fruits and vegetables, as well as animal sources such as milk
products, eggs, and fish oils (National Institutes of Health [NIH], 2016; Reaves, 2015). It is
essential for growth, reproduction, vision, protein synthesis, immune function, and cellular
communication (NIH, 2016; Reaves, 2015). The Dietary Reference Intake (DRI) for vitamin A is
in retinol activity equivalents (RAE) to account for the different bioactivities of vitamin A (NIH,

12

2016). The RDA for men is 900 micrograms (µg) RAE, 700 µg RAE for women, and ranges
from 300-600 µg RAE for infants and adolescents (NIH, 2016). Since vitamin A is a fat-soluble
vitamin, it is not excreted in the urine and can build up in the body, leading to toxicity, or
hypervitaminosis. This can be caused by sudden massive intakes, or chronic excess intakes (NIH,
2016). Symptoms of hypervitaminosis include anorexia; conjunctivitis; headaches; bone and
muscle pain; dry, itchy skin; coma; and even death (NIH, 2016; Reaves, 2015). High betacarotene intake is not toxic, but can result in yellowing of the skin (NIH, 2016). These conditions
rarely result from dietary intakes, but rather supplementation use. The Food and Nutrition Board
therefore established a tolerable upper intake level for vitamin A, excluding beta-carotene,
ranging from 600 µg RAE (2,000 IU) to 900 µg RAE (3,000 IU) for infants and young children,
ranges of 1,700 µg RAE (5,667 IU) to 2,800 µg RAE (9,333 IU) for adolescents and young
adults, and 3,000 µg RAE (10,000 IU) for adults aged 19 and older (NIH, 2016). Individuals
need to be cautious that their intake does not exceed the tolerable upper limit of vitamin A.
Types and Roles of Vitamin A
There are two distinct categories of vitamin A: retinoids and carotenoids. Retinoids are
essential to the diet, while carotenoids are considered non-essential, but do have functions and
benefits when ingested, nonetheless. Retinoid forms of vitamin A are important for cell
differentiation, including cells lining the epithelium (Reaves, 2015). Retinoic acid helps maintain
both normal structure and function of epithelial cells (Gropper, Smith, & Groff, 2009). There are
many different cell types lining the epithelium, all of which have specific functions. A lack of
vitamin A can affect cell formation, which can negatively impact mucous membranes lining the
gastrointestinal tract, the skin, and the respiratory tract (Reaves, 2015). For a person who is
immunocompromised, such is the case in HIV-positive individuals, maintaining a healthy
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epithelium is crucial for protecting against pathogens which can cause serious life threatening
illnesses, since the skin and mucous membranes are immune defenses. In addition, countless
studies show that diarrheal diseases are a major cause of morbidity and mortality in HIV-positive
individuals, especially in other countries, making epithelial cells and gut health an even more
important factor in HIV.
Retinoic acid is also thought to regulate proliferation and differentiation of myeloid
precursors (Gropper et al., 2009). In the presence of vitamin A, myeloid progenitors differentiate
into myeloid dendritic cells. Dendritic cells present antigens to other immune cells, such as T
cells, to enhance the body’s immune response (Gropper et al., 2009). In the case of vitamin A
deficiency, this process, therefore immune system function, is altered. Additionally, vitamin A
deficiency decreases resistance to infection, due to compromised cell signaling in immune cells
(Reaves, 2015). Cell signaling involves communication between cells by means of extracellular
signaling molecules that are produced and released by signaling cells (Nogales, 2008). These
molecules recognize and bind receptors on target cells, where they cause a response through a
signal transduction pathway (Nogales, 2008). In addition, retinoic acid stimulates phagocytic
activity and cytokine production and maintains natural killer cell concentrations, all critical
components of the immune system (Gropper et al., 2009). Cytokines are hormone-like proteins
that stimulate and regulate cells to activate and regulate the innate and immune response
(Murray, Rosenthal, & Pfaller, 2013). Natural killer cells target cells that lack specific cellsurface receptors that are on cells of the body, and induce apoptosis to those foreign cells
(Shields, 2015). Depletion studies have shown that vitamin A appears to be needed for T
lymphocyte function and antibody response to viral, parasitic, and bacterial infections; therefore,
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individuals with vitamin A deficiency have reduced ability to resist and fight infections (Gropper
et al., 2009).
Beta-carotene (a carotenoid) can be used as an antioxidant in the body. It is also
converted to retinoic acid, and can perform functions of other forms of vitamin A such as cell
proliferation, growth, and enhancing cell-mediated immune functions (Gropper et al., 2009).
Since vitamin A plays so many pivotal roles, low intake levels can have serious health
implications, especially for those who are HIV positive. For instance, according to Giraldo
(2002), there are a growing numbers of scientific trials that implicate low serum vitamin A levels
as a risk factor for HIV-positive individuals to progress to the clinical manifestations of AIDS
(Giraldo, 2002). Multiple studies have been conducted to evaluate the effect of vitamin A on
mortality, morbidity, and progression to AIDS in HIV-positive individuals.
Vitamin A Deficiency
Retinol is the predominant form of vitamin A circulating in the blood (WHO, 2011). In
response to tissue demand, it is released from the liver, bound to retinol-binding protein. This
complex combines with transthyretin, and is carried through the blood to specific receptors on
target cell surfaces, thereby regulating many critical body functions (Gropper et al., 2009; WHO,
2011). Blood concentrations remain fairly stable over time, unless an individual chronically
consumes inadequate vitamin A (Gropper et al., 2009). This makes it fairly difficult to use
plasma retinol as a biomarker for inadequate intake, unless liver stores of vitamin A have been
depleted, but it is still used to assess deficiency. Normal plasma values range from 1.05 to 3
µmol/L, while deficiency is typically classified as less than 0.07 µmol/L (Gropper et al., 2009;
WHO, 2011). Concentrations of 0.07 to 1.05 µmol/L may show marginal deficiency in some
people (NIH, 2016). Typical manifestations of vitamin A deficiency include xerophthalmia,
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anorexia, retarded growth, compromised immunity with increased susceptibility to infections,
and keratinization of epithelial cells of the skin with accompanying failure of normal
differentiation (Gropper et al., 2009). Xerophthalmia is characterized by dryness of the eye and
abnormalities of the conjunctiva and cornea of the eye, in addition to Bitot’s spots, conjunctival
and corneal xerosis, corneal scarring and ulcerations, and night blindness (Gropper et al., 2009).
Vitamin A deficiency is the leading cause of preventable childhood blindness, and approximately
half of all children who become blind will die within 12 months of losing their sight (WHO,
2011).
Vitamin A deficiency is not very common amongst developed countries. However, it is a
serious issue in many parts of the world, often because they have limited access to animal
products and cannot afford available foods that contain vitamin A (NIH, 2016). The World
Health Organization estimates that 250 million preschool-aged children and 19.1 million
pregnant women have serum retinol concentrations below 0.70 µmol/L (NIH, 2016; WHO,
2016). On the following page, Figure 4 shows a map of vitamin A deficiency prevalence from
1995 (WHO, NDc).
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Figure 4. Countries categorized by degree of public health
importance of vitamin A deficiency. From WHO (NDc).

Although this map is somewhat outdated, prevalence rates have not fluctuated. Areas of
the globe that have higher rates of vitamin A deficiency are less developed. Additionally, darker
areas on this map seem to correlate well with HIV prevalence illustrated earlier.
Deficiency is particularly widespread among children in developing countries (Semba et
al., 1993). However, Semba et al. (1993) conducted a study on HIV-infected individuals in an
urban population in the developed world, and found an extremely high prevalence (>15%) of
vitamin A deficiency among these individuals (Semba et al., 1993). These researchers believe
that a new situation regarding vitamin A deficiency may be evolving with the global pandemic of
HIV infection (Semba et al., 1993). Unfortunately, the association between vitamin A status and
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infectious diseases is a vicious cycle. While vitamin A deficiency increases susceptibility to
infectious diseases such as measles, chicken pox, tuberculosis, pneumonia, and diarrhea,
episodes of infection seem to deplete vitamin A stores as well (Semba et al., 1993). This has
significant consequences when related to HIV infection. Individuals infected with HIV who also
have vitamin A deficiency may be at higher risk of infection or death due to HIV-related immune
impairment and immune dysfunction associated with low levels of vitamin A (Semba et al.,
1993).
Effect of Vitamin A on HIV/AIDS
As with many scientific findings, results are often controversial between and within
studies. Studies related to vitamin A are no exception. Although results may be inconsistent, they
are no less significant.
Vitamin A and Mortality Rates
Multiple studies have examined the effects of vitamin A and mortality rates. Areas of
Africa are often of interest for researchers, since their rates of vitamin A deficiency and HIV
prevalence are higher than many other countries. Zimbabwe has been of particular interest for
multiple studies. At the time a particular study by Humphrey et al. (2006) was being conducted,
WHO classified Zimbabwe as “high-risk” for vitamin A deficiency, and this country had an adult
HIV prevalence of 25.8% (Humphrey et al., 2006). A clinical trial to examine the effect of
vitamin A supplementation given to women and their infants, on mother-to-child transmission
(MTCT) of HIV, child HIV infection, and infant mortality was appropriate here. This study
recruited a total of 14,110 mother-infant pairs, and had a two by two factorial design, where pairs
were randomized to four different treatment groups (Humphrey et al., 2006). The treatment
groups were Aa, Ap, Pa, and Pp, where “A” was maternal vitamin A supplementation (400,000
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IU), “P” was maternal placebo, “a” was infant vitamin A supplementation (50,000 IU), and “p”
was infant placebo (Humphrey et al., 2006). A single large dose of 400,000 IU postpartum was
chosen based on the data that the existing WHO recommendation of 200,000 IU was too small to
reverse deficiency, and a previous study that used a dose of 400,000 IU was well tolerated
(Humphrey et al., 2006). At baseline, mothers were tested for HIV. Infants’ blood was drawn at
every visit, and the last available blood sample at the end of follow up was tested for HIV. If the
last available sample was negative for HIV, the infant was classified as HIV negative; if the last
available sample was positive for HIV, past samples were tested to determine the timing of
infection (Humphrey et al., 2006). Approximately 60% of the women in all treatment groups had
serum retinol levels less than 1.05 µmol/L at delivery. Although a plasma vitamin A level of 0.7
µmol/L has traditionally been used to determine low serum retinol and define vitamin A
deficiency, evidence has suggested biological function is not optimal at levels less than 1.05
µmol/L so this study used 1.05 µmol/L to define deficiency (Semba et al., 1993). HIV testing and
ART for HIV positive women were not available at the time of recruitment. Follow up visits
were conducted at six weeks, three months, and then every three months for 12 to 24 months
(Humphrey et al., 2006).
This study found that of the 4,495 HIV-exposed infants, 866 died during the 24 months
after delivery, and 621 (71.1%) of those who died were HIV-positive before death. Vitamin A
treatment group was not significantly associated with mortality after adjustment for confounders
(Humphrey et al., 2006). This result is shown in Table 2 on the following page.
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Table 2. Proportional hazards ratios for risk of death by 24 months in all
infants born to HIV-positive mothers.

From Humphrey et al. (2006).

They also found that in IU infants (infants who are HIV positive at baseline), neither
maternal nor infant vitamin A supplementation significantly reduced mortality (Humphrey et al.,
2006). The severity of the HIV infection may be too overwhelming for vitamin A to have an
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effect at this stage of the infant’s infection. However, in IP infants (infants who are HIV negative
at baseline and HIV positive at 6 weeks), infant supplementation significantly reduced mortality
at 24 months, by 28% (Humphrey et al., 2006). An effect of similar magnitude was found in both
groups who received neonatal supplementation, while maternal supplementation had no
significant effect on mortality on these children. Interestingly, in infants who were HIV negative
at baseline and six weeks, all three vitamin A supplementation regimens approximately doubled
the risk of death by two years of age (Humphrey et al., 2006). This could potentially be
explained if priming with vitamin A increases viral load in those who become infected during
breast-feeding, thereby hastening their progression to death, which has been explored in other
studies (Humphrey et al., 2006). The results of the current study are shown in Table 3 below.
Table 3. Adjusted child mortality risk, by vitamin A treatment group and HIV status

From Humphrey et al. (2006).
Overall, this study suggests that timing of vitamin A supplementation may be a factor on its
effect on HIV progression and mortality, and that it may have a protective effect on infant
mortality, but may also increase risk of death in infants who are HIV negative.
21

Another study examined the plasma vitamin A levels in a cohort of HIV-negative and
HIV-positive intravenous (IV) drug users (Semba, Graham, Caiaffa, Margolick, Clement, &
Vlahov, 1993). Two (3.7%) of the 53 HIV-seronegative IV drug users and 19 (15.1%) of the 126
seropositive individuals had plasma levels less than 1.05 µmol/L (Semba et al., 1993). The
researchers reported that among HIV-seropositive individuals, plasma vitamin A levels less than
1.05 µmol/L were associated with a significantly increased risk for mortality of 4.3, after being
adjusted for confounding variables (Semba et al., 1993). Additionally, vitamin A deficientindividuals had significantly decreased mean survival times. These results are shown in Table 4
below and Figure 5 on the following page.
Table 4. Relative risk of mortality among HIV-positive individuals

From Semba et al. (1993)
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Figure 5. Survival of HIV-positive individuals according to vitamin A level.
Broken line indicates group with normal vitamin A levels (>1.05 µmol/L); solid
line indicates group with deficient vitamin A levels (< 1.05 µmol/L). Mean
survival time of 50.3±1.1 for the group with normal vitamin A levels was
significantly higher than 39.0±4.3 months for the group with vitamin A deficiency
by the log rank test (P<.001). From Semba et al. (1993)
The authors of this study concluded that vitamin A deficiency was much higher in
individuals infected with HIV, compared to HIV-negative individuals. Additionally, individuals
who were vitamin A deficient had significantly increased mortality rates and decreased survival
times (Semba et al., 1993). The authors suggest that these results are likely due to the central role
vitamin A plays in immune function, although additional studies are needed to determine this to
be the case.
In a more recent study (2005), Semba et al. examined the effect of vitamin A
supplementation on mortality and morbidity in HIV-infected children in Uganda (Semba et al.,
2005). This was a randomized, double-blind, placebo-controlled trial that assessed the effects of
giving large-dose vitamin A supplements (60 mg RAE) every three months to HIV-infected
children between the ages of 15 and 36 months, with a mean follow-up of 17.8 months after age
15 months (Semba et al., 2005). Infants did not receive antiretroviral medications or other
micronutrient preparations during the trial. At the start of the study, there was no general vitamin
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A distribution program in Uganda for school-aged children, aside from administration of vitamin
A capsules with measles immunizations and for children with measles (Semba et al., 2005).
However, the trial was ceased on February 1, 2001 once the Uganda Ministry of Health changed
their guidelines to recommend that all preschool aged children in the country receive 60 mg RAE
(equivalent to 60,000 µg) every six months (Semba et al., 2005). The researchers found that
vitamin A supplementation significantly decreased the mortality rates by 46% in HIV-infected
children compared to placebo (Semba et al., 2005). Fawzi et al. (1999) found similar results in a
randomized, placebo-controlled clinical trial in HIV-positive and negative children in Tanzania
(Fawzi et al., 1999). Researchers in this study determined overall vitamin A supplementation to
significantly reduce mortality by 49%, and reduced all-cause mortality by 63% in HIV-infected
children and by 42% among HIV-negative children (Fawzi et al., 1999). Additionally, vitamin A
supplementation as associated with a 68% reduction in AIDS-related deaths and a 92% reduction
in diarrhea-related deaths (Fawzi et al., 1999).
It appears that many studies have found vitamin A supplementation to decrease mortality
rates in HIV-infected individuals, regardless of age, drug use, or vitamin A status. Although
results vary by study, and Humphrey et al. (2006) found timing of infection to be a significant
indicator of whether or not vitamin A supplementation reduced or increased mortality rates, it is
apparent that vitamin A status and/or supplementation has positive results on the mortality of
HIV-infected individuals. However, it is unknown the best methods, dosage, and frequency of
supplementation to determine if vitamin A could ultimately decrease mortality in HIV-positive
individuals, although most studies conclude that vitamin A supplementation, an inexpensive
intervention, should be included as a standard care and may reduced mortality rate in HIVinfected individuals (Fawzi et al, 1999; Humphrey et al, 2006; Semba et al., 2005).
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Vitamin A and Morbidity
A double-blind, randomized, placebo-controlled clinical trial evaluated the effect of
vitamin A supplementation on morbidity in children born to HIV-infected women in Africa
(Coutsoudis, Bobat, Coovadia, Kuhn, Tsai, & Stein, 1995). Mothers were given a card on which
to record illnesses experienced by the child. Children received full clinical examinations, and all
morbidity in the past month was recorded at each visit (Coutsoudis et al., 1995). Mothers were
closely interviewed to ensure the definition of each disease. The incidence, duration, and severity
(hospital admission) of the following were recorded: diarrhea, upper-respiratory tract infection,
lower-respiratory tract infection, isolated fever, thrush, and rash (Coutsoudis et al., 1995).
Mothers were asked to follow up at clinics at two and three months of age, and thereafter at
three-month intervals up to 18 months of age. Home visits were made to those who did not
follow up (Coutsoudis et al., 1995). At one and three months, infants orally received 50,000 IU
(15,000 µg) of vitamin A as retinyl palmitate, or an equal volume of placebo, and at six and nine
months they received 100,000 IU (30,000 µg) of vitamin A or placebo. At 12 and 15 months, the
children were given either 200,000 IU (60,000 µg) of vitamin A and 40 IU of vitamin E as an
antioxidant, or a placebo with 20 IU of vitamin E (Coutsoudis et al., 1995). Positive diagnosis of
HIV infection in children was determined at 15 months via an HIV antibody test.
The results showed a significant reduction in overall morbidity of 31% in all infants
receiving supplementation (Coutsoudis et al., 1995). However, for almost all conditions assessed
separately, rates with supplementation were lower, but were not of significance. In the
supplemented group, incidence was reduced for all diarrhea by 29%, for diarrhea lasting more
than seven days by 38%, and for hospital administration for diarrhea by 77%. Differences for
thrush and respiratory infections were smaller, and no difference in rash was noted (Coutsoudis
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et al., 1995). These results are illustrated in Table 5 below.
Table 5. Morbidity for all infants (infected, uninfected, and status
not established) and vitamin A vs. placebo group.

From Coutsoudis et al. (1995).
Additionally, among HIV-infected children, vitamin A supplementation resulted in a
significant reduction of 49% for all diarrhea (Coutsoudis et al., 1995). There was a 56%
reduction for diarrhea lasting more than seven days, and a 77% reduction for hospital admissions
for diarrhea, all of which were among HIV-infected children, although these results again were
not statistically significant (Coutsoudis et al., 1995). Table 6 on the following page displays
these results (Coutsoudis et al., 1995).

26

Table 6. Morbidity rates per 100 child-months of follow up among
known HIV-infected and uninfected children: vitamin A vs. placebo

From Coutsoudis et al. (1995).
Separate analysis of morbidity occurring below six months of age, at seven through 12 months of
age, and at 13 through 18 months of age found similar effects of treatment (Coutsoudis et al.,
1995).
These results showed a significant decrease in all morbidity for all infants (31%) and in
all diarrhea for HIV-infected infants (49%) receiving vitamin A supplementation (Coutsoudis et
al., 1995). Other decreases in morbidity were examined, particularly related to diarrhea, although
results were not significant. These finding suggests a decrease in severity of disease rather than
incidence. This is a crucially important finding, as diarrhea is among the main causes of
morbidity and use of health services, and in Africa, an important cause of death among HIVinfected children (Coutsoudis et al., 1995). The likely mechanisms through which vitamin A
decreases morbidity is that it increases mucosal integrity and boosts the immune response, as
these barriers are known to be breached in HIV infection (Coutsoudis et al., 1995). Specifically,
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a decrease in CD4+ T cell counts correlates with risk and severity of HIV-related diseases, which
can eventually lead to progression of AIDS (Coutsoudis et al., 1995).
In concurrence to the study by Coutsoudis et al. (1995), Semba et al. (2005) also did not
find significant results of vitamin A supplementation on the morbidity of HIV-infected children
in Tanzania (Semba et al., 2005). These results can be seen in Table 7 below.
Table 7. Modified point prevalence per child-month follow-up.

From Semba et al. (2005).
Vitamin A supplementation had no significant effect on modified point prevalence of
diarrhea, cough, fever, or blood in the stool in the previous seven days, or reported
hospitalizations (Semba et al., 2005). However, there was a significant association between
vitamin A supplementation and a decrease in persistent cough lasting longer than 30 days, and a
trend toward a decrease in diarrhea lasting longer than 30 days, although this was not of
significance (Semba et al., 2005). Coutsoudis et al. (1995) found a significant reduction in
diarrheal morbidity with vitamin A supplementation, while Semba et al. (2005) merely
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discovered a trend in vitamin A supplementation and diarrhea, which was not of significance
(Coutsoudis et al., 1995; Semba et al., 2005). In addition, Semba et al. (2005) did not analyze all
morbidity, while Coutsoudis et al. (1995) found a significant reduction in all morbidity in all
infants, but not in HIV-positive infants (Coutsoudis et al., 1995; Semba et al., 2005). These
studies suggest there might be evidence supporting vitamin A supplementation and reduced
diarrheal morbidity among HIV-infected children, although the data is not particularly strong.
From what has been researched thus far, it does not appear that vitamin A supplementation
affects other morbidities amongst HIV-positive children. The author of this paper could not find
many studies examining the effect of vitamin A status or supplementation on morbidity, and one
of the studies mentioned is rather outdated. Therefore, additional research needs to be conducted
to determine if vitamin A supplementation can reduce morbidity among HIV-positive
individuals.
Vitamin A and T Cell Counts
In the study conducted on IV drug users, Semba et al. (1993) found that lower CD4 cell
counts (<200 cells/µL) were associated with lower vitamin A levels among HIV-seronegative
and seropositive individuals (Semba et al. 1993). The HIV-negative individuals with CD4 T cell
counts more than 1000 cells/µL had mean vitamin A levels of 2.12 µmol/L compared with 1.73
µmol/L in individuals with CD4 cell counts less than 1000 cells/µL (Semba et al., 1993).
Seropositive individuals with CD4 cell counts greater than 200 cells/µL had mean vitamin A
levels of 1.57 µmol/L, while HIV-positive individuals with less than 200 CD4 cells/µL had mean
vitamin A levels of 1.28 µmol/L (Semba et al., 1993). On the following page, Table 8 illustrates
these values, which are statistically significant (Semba et al., 1993).

29

Table 8. Vitamin A status and CD4 cell levels in HIV-positive individuals. NS
indicates not significant.

From Semba et al. (1993).
In addition, these researchers reported that low CD4+ cell counts were associated with a
higher mortality of 10.0, which is shown in Table 4., Relative risk of mortality among HIVpositive individuals, in the mortality rates section above (Semba et al., 1993). The increased risk
of mortality in individuals with lower plasma vitamin A levels may be related to the central role
vitamin A plays in immunity and protecting individuals from infectious diseases (Semba et al.,
1993).
One study (1993) investigated the effect of beta-carotene on CD4+ T cell counts in HIV
positive-individuals (Coodley, Nelson, Loveless & Folk, 1993). In this double-blind, placebocontrolled trial, subjects were randomized to receive either 180 mg of beta-carotene or placebo
per day, for the first four weeks of the study. Participants then crossed over to receive the
alternate therapy for the second four weeks (Coodley et al., 1993). A complete blood count,
chemistry battery, serum carotene level, and T cell quantitative subsets were drawn on all
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participants at baseline and the end of week two, week four, week six, and week eight.
Researchers found that beta-carotene was associated with a statistically significant increase in
total white blood cell (WBC) count, percent change in CD4 count, and percent change in
CD4/CD8 ratio compared to placebo (Coodley et al., 1993). The absolute CD4 count, absolute
CD4/CD8 ratio, and the numbers of total lymphocytes and B-lymphocytes increased while
participants were on beta-carotene and fell during the placebo arm, as well; however, these
results did not reach statistical significance (Coodley et al., 1993). Additionally, no significant
sequence effect was detected, suggesting that the order of treatments did not affect results. Worth
noting is that a marginally significant period effect was found for CD4 counts, implying that
CD4 counts dropped slightly during the study, regardless of intervention (Coodley et al., 1993).
Table 9 below shows these results.

Table 9. Comparison of beta-carotene and placebo treatment arms

From Coodley et al. (1993).
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The mean WBC change was +420 while taking beta-carotene, and -600.0 when taking placebo.
The percentage change of CD4 counts of the beta-carotene treatment was +17.0%, while it was
-17.3% during the placebo arm (Coodley et al., 1993). Although results were not of significance,
it is interesting to see the change in individuals’ CD4 cell counts during the beta-carotene and
placebo arms. These results are illustrated in Figure 6 below.

Figure 6. Percent change in individual CD4 counts from baseline after treatment for 4 weeks
with the beta-carotene or placebo grouped by baseline CD4 counts. Patients who completed
only one arm or those with missing data have one value grouped above (5 of 16). White bars
indicate placebo; shaded bars indicate beta-carotene.

The CD4+ T cell counts greatly increased for most individuals while they were taking
beta-carotene, and decreased while on the placebo. The lack of significance may be attributed to
the small sample size of 21 individuals, as other studies have seen significant changes in CD4+ T
cell counts (Coodley et al., 1993). Both treatments were well tolerated, and no side effects were
reported aside from noting a slight orange skin color while on beta-carotene. These results, along
with lack of side effects, make beta-carotene a potential interest to increase CD4 counts in HIVpositive individuals. However, the changes noted may not be sufficient for clinical effects,
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although these were not measured in this study. Moreover, it is uncertain whether these effects
would increase, persist, or decrease over time (Coodley et al., 1993).
Contrary to the study conducted by Coodley et al. (1993), a preliminary trial of betacarotene in HIV-positive individuals did not show significant results of beta-carotene
supplementation increasing CD4+ cells (Garewal, Ampel, Watson, Prabhala, & Dols, 1992). The
study consisted of supplementing 11 HIV-seropositive men with 60 mg beta-carotene once daily
for four months (Garewal et al., 1992). The study had a short treatment period, had a small
sample size, and did not implicate use of a placebo, which may have led to these findings
(Garewal et al., 1992). However, results showed increases in the expression of transferrin
receptor, Ia antigen, and a natural killer cell marker (Leu 11), all immune activation markers
(Garewal et al., 1992). Interestingly, the percent of cells expressing these markers only increased
for the first three months of the trial and then decreased during the fourth month, while
participants were still taking beta-carotene (Garewal et al., 1992). Reasons for why this occurred
are unknown, although similar results have been found in previous studies of individuals not
infected with HIV (Garewal et al., 1992). Longer trials are needed in order verify this
observation and to fully assess the duration of the effect (Garewal et al., 1992). This study
suggests that beta-carotene can affect immunologic measurements in HIV-infected subjects,
although CD4+ cells may not be included in those measurements (Garewal et al., 1992). Further
investigation is needed to determine the effects of beta-carotene supplementation on immune
system function in HIV-positive individuals (Garewal et al. 1992).
Vitamin A and HIV Progression
As defined earlier, progression to AIDS occurs when an individual’s CD4+ T cell counts
have fallen below 200 cells/ml of blood or when an individual develops one or more
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opportunistic infections (Martinez, 2015). Many of the studies mentioned previously have
examined the effect of vitamin A status or supplementation on CD4+ cell counts, as well as
mortality and morbidity. However, a few studies have determined the effect of vitamin A on
progression to AIDS, specifically. In 1993, Tang, Graham, Kirby, McCall, Willett, and Saah
examined the effect of dietary micronutrient intake and the risk of progression to AIDS in HIVinfected homosexual men (Tang, Graham, Kirby, McCall, Willet, & Saah, 1993). This
prospective study used food frequency questionnaires to determine the intakes of nutrients such
as total calories, protein, fiber, fat, cholesterol, multiple B vitamins, vitamin A, folate, iron, and
many others. Participants consisted of 1,014 homosexual men who fit eligibility criteria and had
no AIDS defining illness at the start of the study. Participants were followed for a median of 6.8
years (Tang et al., 1993). For vitamin A, the third quartile of intake was associated with a
significant decreased risk of developing AIDS, while the second quartile was also associated
with a lower hazard ratio, although was not significant (Tang et al., 1993). The highest quartile
of intake had a relative hazard close to 1.0 suggesting a U-shaped relationship between vitamin
A intake and risk of AIDS (Tang et al., 1993). Further analysis supported significant results of
this relationship (Tang et al., 1993). Due to the odd finding of the two middle quartiles of intake
having the most beneficial effects, Tang, Graham, Semba, and Saah followed up with another
study in 1997 examining the association between serum vitamin A and E levels and HIV
progression (Tang, Graham, Semba, & Saah, 1997).
This prospective study also assessed usual diet with food frequency questionnaires, and had
sections for recording frequency and amount of vitamin supplements taken, as well as a write-in
section for foods not listed (Tang et al., 1997). Participants included 312 homosexual and
bisexual men from the Multicenter AIDS Cohort Study. Serum vitamin A and E concentrations
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were obtained, and the follow up period lasted for nine years (Tang et al., 1997). Although 29%
of individuals had total intakes of vitamin A (including supplements) below the RDA, there was
no significant difference in risk of progression to AIDS when comparing those in the lowest
quartile of serum vitamin A (<1.82 µmol/L) with those in each of the upper three quartiles (Tang
et al., 1997). Additionally, no difference was observed in the proportions of subjects whose
CD4+ cells declined to less than 200 cells/ml of blood (Tang et al., 1997). However, a majority
of the participants had serum vitamin A levels in the high to normal range (median = 2.44
µmol/L) so it is not surprising that no association was determined, especially when body function
is compromised at levels below 1.05 µmol/L (Tang et al., 1997). Since participants with the
lowest quartile of serum vitamin A levels was greater than the cut off to define deficiency, these
results are not unexpected. Results are shown in Table 10 below.
Table 10. Cox proportional hazards model for serum vitamin and E levels in HIV-positive
homo- and bisexual men. Outcome is time to first AIDS diagnosis.

From Tang et al. (1993).

35

Both of these trials were conducted in developed countries where vitamin A deficiency is
not typically an issue. Additionally, they used similar study populations, thereby decreasing the
applicability to other HIV-positive populations. Regardless, results were significant, although
varied between studies, which puts into question the effect of vitamin A on HIV progression to
AIDS.
Due to the results of these observational studies, as well as others, suggesting
micronutrient status as a determinant for the progression of HIV to AIDS, Fawzi et al. (2004)
conducted a randomized, double-blind, placebo-controlled clinical trial analyzing the effect of
multivitamin supplementation on HIV disease progression (Fawzi et al., 2004). 1,078 HIVinfected pregnant women in Tanzania were enrolled in the study and were followed with respect
to survival for a median of 71 months. Women were randomly assigned to receive an oral dose
of one of four regimens: vitamin A alone (30 mg of beta carotene plus 5,000 IU of preformed
vitamin), multivitamin excluding vitamin A (20 mg of vitamin B1, 20 mg of vitamin B2, 25 mg
of vitamin B6, 100 mg of niacin, 50 µg of vitamin B12, 500 mg of vitamin C, 30 mg of vitamin E,
and 0.8 mg of folic acid), multivitamin plus vitamin A in the same doses listed above, or placebo
(Fawzi et al., 2004). Additionally, at delivery, women in the two groups that received vitamin A
were given an additional oral dose of vitamin A (200,000 IU), whereas the women in the other
two groups received placebo. All children received a dose of vitamin A at six months of age,
according to the standard of care in Tanzania. At the time of the study, antiretroviral therapy was
not available to a majority of the women in Tanzania, including those who participated in this
study (Fawzi et al., 2004). Given early findings in the study indicating beneficial effects of the
multivitamin regimen reducing adverse outcomes during pregnancy, all women who became
pregnant after May 1998 were given open label multivitamins during pregnancy, and resumed
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their pre-pregnancy blinded regimen after delivery. Additionally, the data and safety monitoring
board recommended that vitamin A be dropped from the two vitamin A treatments due to the
finding that maternal vitamin A supplementation increased transmission of HIV to children, a
finding that was under study at the start of the trial (Fawzi et al., 2004). Women previously
receiving vitamin A were then given placebo.
Results showed that vitamin A supplementation alone had small effects on the risk of
progression to AIDS, and for the most part was not significantly different when compared to
placebo (Fawzi et al., 2004). However, women in the multivitamin group were 29% less likely to
progress to WHO-defined stage 4 HIV or die of AIDS-related causes, which was of statistical
significance (Fawzi et al., 2004). Interestingly, when the multivitamin was taken in addition to
vitamin A, benefits with regard to the various end points examined were reduced. Results can be
found in Table 11 on the following page.
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Table 11. Relative risks of disease progression and death from AIDS-related causes among HIV-infected
women receiving one of the three vitamin regimens, as compared with women in the placebo group.

From Fawzi et al. (2004).

Although no evidence was found to support previous studies’ results that vitamin A may reduce
the risk to disease progression, and in fact negative affects on HIV transmission to children were
found, another potential candidate to be used as a form of HIV therapy was discovered. These
researchers determined the cost of a multivitamin supplement as a way to treat HIV, and found a
year’s supply would cost approximately $15, and wholesale prices would be substantially lower
(Fawzi et al., 2004). Compared to the $300 to $3700 per month cost of ART, which is not even
available to a majority of HIV-infected individuals, multivitamin supplementation could be a
low-cost treatment with virtually no side effects, granted further research is conducted on the
topic.
38

Summary and Future Research
HIV is a growing pandemic. Although rates of infection have stabilized, there were still
an estimated 2.0 million new infections in 2014 globally (WHO, 2015). We may be close to
finding a prevention or cure for HIV/AIDS, but until then, other measures must be taken in order
to help those who are infected and who may become infected. Antiretroviral therapy has
revolutionized HIV infection, and has allowed for individuals to live longer and more normal
lives than they could have expected upon being infected a mere 20 years ago. Unfortunately,
ART has many negative complications, and a significant proportion of individuals cannot afford
the treatment. Much research has gone into finding other potential treatments, such as vitamin A.
Vitamin A is an inexpensive intervention and is simple to administer. It can strengthen immune
responses, might reduce severity of infectious diseases, and perhaps can prolong life (Coutsoudis
et al., 1995). An array of more research is necessary in order to use vitamin A, or any other
vitamin or mineral as a means of treatment. Many of the studies mentioned above either had
short treatment lengths or small study populations. Different trials used different types and
amounts of vitamin A, and all had diverse results, and even examined different outcomes
including CD4+ cell counts, mortality rates, morbidity, and progression to AIDS. Other studies
merely observed plasma vitamin A levels without intervening. Of particular concern is the fact
that many of these studies were conducted a decade or two ago, and that more recent research is
not currently available. Review articles that were written in more recent years cite the same
studies repeatedly, all of which took place in the early 1990s to 2000s. It is possible that more
time and money has gone into research of ART or other forms of treatment. However, the current
author finds it concerning that significant results were found, particularly related to vitamin A
supplementation and reduced mortality and morbidity among HIV-infected individuals, and yet
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no policies have been implemented to supplement HIV-positive individuals and use vitamin A as
an adjunct to treatment for HIV infection.
A few countries, including Uganda and Tanzania, have begun vitamin A supplementation
in children at the age of six months to reduce the risk of mortality and morbidity from vitamin A
deficiency alone (Fawzi et al., 2004; Semba et al., 2005). It would be interesting to assess the
association of the start of vitamin A supplementation in children and HIV incidence in years to
come. According to WHO, the only current recommendation regarding vitamin A
supplementation is for infants and children aged six to 59 months who live in areas where the
prevalence of vitamin A deficiency is more than 20% (WHO, 2011). All other age groups,
including newborns and infants aged one to five months, pregnant women, pregnant women with
HIV infection, and postpartum women, are not currently recommended to take vitamin A
supplementation as a means to prevent morbidity and mortality (WHO, 2011).
It is apparent that many more studies altering different aspects mentioned above are
needed in order to make appropriate recommendations regarding vitamin A and HIV infection.
This author suggests that researchers should look into vitamin A, as well as other vitamins, as
being more than “just a vitamin;” perhaps there is some component in these molecules we have
not discovered, that could unleash unimaginable opportunities regarding nutrition and disease
prevention. Funding is scarce and the work is difficult, but finding cures for diseases such as
HIV/AIDS is important to quality of life for all of human kind.
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